What were the key takeaways from Lemaitre Vascular's earnings call?

What were the key takeaways from Lemaitre Vascular’s earnings call?

What is Lemaitre Vascular's gross profit margin?

What factors drove the changes in Lemaitre Vascular's revenue and profit?

What guidance did Lemaitre Vascular's management provide for the next earnings period?

What does Lemaitre Vascular do and what are its main business segments?

Did Lemaitre Vascular beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Lemaitre Vascular year over year?

- **Top Line Growth**: 12% organic sales driven by grafts (23%) and shunts (18%), with 10% price contribution.
- **Autograft Success**: Q3 sales $1.4M, Q4 guidance $2M, targeting 2026 European approvals.
- **Margin Expansion**: Adjusted gross margin 70.8% (up 300bps YoY), operating margin 28%.
- **Strategic Moves**: 34,000 sq ft distribution center opening, 8% U.S. price list increase.
- **Risk Note**: FDA warning letter with no production impact, FX headwinds in Q4.

**【CEO Summary Section】**
- **Organic Sales Growth**: 12% YoY, driven by 23% grafts and 18% shunts. Price contributed 10%, units 2%. Excluding catheters, growth was 14%.
- **Autograft Performance**: Q3 sales $1.4M (vs. Q2 $0.42M), Q4 guidance $2M. Global growth 33%, targeting 2026 approvals in Canada, Korea, and Irish distribution.
- **Salesforce Expansion**: 152 reps at quarter-end, 23 open roles, targeting 165 by year-end. 55% North American revenue subject to price floors.
- **International Strategy**: 8% U.S. price list increase, 34,000 sq ft distribution center opening Q1 2026. Direct sales expansion in Europe (e.g., Ireland, Czechia).

**【CFO Financial Commentary】**
- **Financial Results**: GAAP net income $17.4M, operating margin 33%. Adjusted gross margin 70.8% (up 300bps YoY). Operating expenses $26.3M (+9% YoY), guided for H2 decrease.
- **Guidance Update**: Full-year revenue $248M (+13%), adjusted EPS $2.37 (+22%). Gross margin 70.3%, operating margin 26%.
- **One-Time Impact**: $4.8M employee retention tax credit reduced COGS by $2.7M, operating expenses by $0.7M.
- **FDA Update**: New Jersey facility received warning letter, no production disruption.

**【Q&A Highlights】**
- **Growth Drivers**: Autograft Europe rollout, South Africa AV access adoption. FX (euro weakness) reduced Q4 guidance by $0.6M.
- **Gross Margin**: Pricing, mix (Autograft, Z-Medica exit), manufacturing efficiencies. 2026 focus on biologics (e.g., XenoSure).
- **M&A Strategy**: No immediate M&A, maintaining standards. Cash balance $343M, dividend $4.5M.
- **R&D Spend**: 2026 R&D as % of sales may increase, balancing op margin growth.
- **Salesforce Management**: Performance-based hiring, 8 reps exited for underperformance.


LeMaitre Vascular, Inc. (LMAT) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: 15% YoY growth driven by catheters (+27%), grafts (+19%), and international expansion (EMEA +23%).
- **Product Momentum**: Artegraft Q2 sales $420K (Q1: $185K), full-year guidance $2M. RestoreFlow cardiac unit growth 61%.
- **Guidance Uptick**: Full-year sales $251M (+15% organic), EPS $2.30 (+19%), supported by 70% gross margin and 25% operating margin.
- **Strategic Moves**: Dublin distribution center for Europe, 23 new sales reps, and 25% China price hike to offset tariffs.
- **Regulatory Wins**: Artegraft approved in 9 countries, XenoSure China submission Q4, RestoreFlow targeting Ireland/Germany approvals.


**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue increased 15% YoY, driven by 27% growth in catheters and 19% in grafts. EMEA led with 23% growth, followed by Americas (12%) and APAC (12%).
- **Product Highlights**: Artegraft sales reached $420,000 in Q2, up from $185,000 in Q1, with full-year guidance of $2 million. RestoreFlow unit sales grew 61% in the U.S., and XenoSure cardiac patches saw 9% growth in Europe.
- **International Expansion**: Artegraft approved in 9 countries, with 2026 targets for Canada, Korea, and Singapore. A RestoreFlow distribution center is opening in Dublin.
- **Guidance Update**: Full-year sales raised to $251 million (15% organic growth), gross margin to 69.7%, operating income to $60.9 million (+17%), and EPS to $2.30 (+19%).

**【CFO Financial Commentary】**
- **Financial Performance**: GAAP net income $13.8 million (+17% YoY), EPS $0.60 (+16%). Gross margin 70% (up 110bps YoY) due to higher ASPs and manufacturing efficiencies.
- **Cost Structure**: Operating expenses $28.8 million (+20% YoY) driven by 23 new sales reps and European go-direct efforts. Operating margin 25%.
- **Cash Flow**: Record $20.3 million cash from operations, ending Q2 with $319.5 million in cash. Dividends paid $4.5 million.
- **Tariff Impact**: Implemented 25% price increase in China, with no material impact expected in H2 due to U.S.-only manufacturing.

**【Q&A Key Highlights】**
- **Catheter Stocking Orders**: $800,000 Q2 impact from recall-related stocking, not expected to repeat in Q3.
- **Price Growth Sustainability**: 8% Q2 price growth; 2026 hikes to follow historical cadence but not yet committed.
- **Unit Growth Drivers**: Excluding catheters, 5% unit growth (aligned with 2023-24 trends). RFA cardiac up 61%, Artegraft Europe strong.
- **Sales Force Expansion**: Target 165 reps by year-end (164 as of Q2), focused on Europe and APAC. No specialized teams; all carry full product line.
- **Regulatory Pipeline**: XenoSure vascular patch final submission in Q4 for 2026 China approval. RestoreFlow seeking Ireland/Germany approvals, with 2026 Canada, Korea, Singapore targets.
- **R&D Spending**: 6% of revenue in Q2, expected to rise post-MDR compliance. Focus on niche markets with high market share.


LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript

- **Revenue Beat & Guidance Uptick**: 13% organic growth vs. prior 10% target, driven by grafts and shunts; 2025 sales raised to $245M.
- **Gross Margin Expansion**: 69.2% gross margin (+60bps YoY) from ASP hikes and cost control.
- **European Growth Catalyst**: Autograph CE mark enables $8M European opportunity, with Q1 international sales $180K.
- **Tariff Resilience**: 100% US manufacturing limits risk; 40% international sales buffer via pricing flexibility.
- **Salesforce Surge**: 170 reps target vs. 137 in Q1 2024, with reps ramping to quota in ~2 months.


**【CEO Business Overview】**
- Q1 2025 organic sales growth of 13%, driven by 17% growth in grafts and 14% in carotid shunts, with record sales across all five product categories.
- Expanded sales force to 164 reps (targeting 170 by year-end) and 34 sales managers, with new offices in Zurich and Lisbon to support direct sales in Europe.
- Secured CE mark for Autograph, enabling European launch; anticipate $8M market in Europe and ROW, with US sales of $37M in 2024.
- Raised 2025 reported sales guidance to $245M (from $239M) and organic growth to 13% (from 10%), supported by $303M cash reserve.

**【CFO Financial Highlights】**
- Q1 2025 GAAP net income of $420M, with 69.2% gross margin (+60bps YoY) driven by 9% ASP increase, lower scrap, and production efficiency.
- Operating expenses rose 16% YoY to $28.8M due to 21 new sales hires and related costs, offset by 10% operating income growth to $12.6M.
- Ended Q1 with $302.5M cash, +$9M from operations, despite $4.5M dividends and $1.4M acquisition payment.
- Tariff impact: $825K annualized China COGS increase, partially offset by May price hikes; 40% international sales buffer via pricing flexibility.

**【Q&A Key Takeaways】**
- **Tariff Strategy**: 100% US manufacturing limits exposure; 25% COGS from foreign suppliers ($2M/Australia). China sales <1%, with long-term optimism for medical device tariffs.
- **Autograph Launch**: Q1 international sales $180K; anticipate €350K in H2. European approvals in Ireland/Germany to accelerate RestoreFlow expansion.
- **Salesforce Efficiency**: Reps ramp to quota in ~2 months; 2025 target of 170 reps vs. 137 in Q1 2024 reflects strategic investment in growth.
- **M&A Outlook**: Seeking $15-50M revenue targets in open vascular or cardiac crossover; $300M+ cash provides flexibility despite cautious market valuations.
- **China Dynamics**: Xenosure cardiac approval in Dec 2024; pursuing provincial listings for 2026 sales, despite geopolitical tensions.


LeMaitre Vascular (LMAT)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue Surge**: 14% Q4 growth driven by grafts, shunts, and catheters, with strong international expansion (APAC +21%, EMEA +18%).
- **Salesforce Expansion**: Targeting 165 reps by end-2025, with 2/3 U.S. hires focused on territory splitting.
- **Regulatory Milestones**: 16 MDR CE marks secured; Artegraft CE Mark expected H1 2025, enabling $8M European market access.
- **Financial Strength**: $300M cash, 25% dividend increase, and 2025 guidance of 10% organic sales growth.
- **China Play**: XenoSure launch in H2 2025 with potential long-term upside.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue grew 14% YoY, driven by grafts (23%), shunts (14%), and catheters (12%). Geographically, APAC (+21%), EMEA (+18%), and Americas (+12%) all contributed.
- **Salesforce Expansion**: Ended Q4 with 152 reps (+12% YoY), targeting 165 by end-2025. Added 31 managers (+29% YoY). New offices in Shanghai (China) and Switzerland to support international growth.
- **Regulatory Progress**: 16 of 23 MDR CE marks obtained; Artegraft CE Mark expected H1 2025. XenoSure launched in China H2 2025 with $8M European market opportunity.
- **Leadership Transition**: J.J. Pellegrino retiring; Dorian LeBlanc to replace as CFO March 10, 2025.

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP net income $11.2M, Non-GAAP EPS $1.08. Gross margin 69.3% (+120bps YoY) due to higher ASPs, manufacturing efficiencies, and quality cost control.
- **Cash Position**: $300M in cash and securities (+$176M Q4, driven by $168M convertible offering proceeds).
- **2025 Guidance**: Organic sales +10%, gross margin 69.7%, operating income $59.8M (+15%), EPS $2.24 (+16%).
- **Dividend Increase**: $0.20 quarterly dividend (+25%).

**【Q&A Highlights】**
- **Pricing Strategy**: U.S. list price increase 8% in January; worldwide actual price increase expected ~6-7%. Historical overperformance noted but cautious on 2025.
- **Salesforce Cadence**: 13 reps added in 2025 (2/3 U.S., 1/3 international). Focus on splitting large U.S. territories and new markets like Portugal, Czechia.
- **China Launch**: XenoSure sales expected H2 2025 after reimbursement and provincial listings. Minimal impact on 2025 guidance.
- **Tariffs**: Minimal risk due to U.S.-based manufacturing; China sales <1% of total.
- **M&A Strategy**: Open to acquisitions in cardiac/vascular with differentiated devices; no preference for U.S. vs. international approvals.

LMAT

LMAT fundamentals

Earnings Call

You can ask Aime